The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
|Articles|July 15, 2022
News Roundup: July 11 to July 15
Author(s)Miranda Hester
Your weekly roundup of the latest news from Drug Topics®.
Advertisement
FDA Issues EUA for Novavax COVID-19 Vaccine, Adjuvanted
Adults aged 18 and older are eligible to receive the vaccine.
Helping Patients Manage Diabetes Burnout
Over time, the emotional burden of managing the disease can become overwhelming.
Prescription to OTC Switches A Boon for Pharmacy Front End
Medications that switch from prescription-only to OTC can be stocked in the pharmacy’s front end.
Specialty Drug Pipeline Updates for 2022
The specialty drug pipeline includes first- and next-in- class drugs across the oncology and immunology spaces.
Novel, Dual-Targeted Treatment for T2D Is FDA Approved
Tirzepatide is a once-weekly subcutaneous injection to treat type 2 diabetes in conjunction with diet and exercise.
Advertisement
Related to this article
The Milken Institute released survey results alongside new data regarding the need for pharmacists in extending effective GLP-1 care.
Through the ACCESS program, Mark Ey, RPh, notes that pharmacies can now start billing for a variety of services they’ve already been providing.
The medication significantly increased risk of pregnancy loss when compared with macrolide antibiotics, amoxicillin, and topical clindamycin for acne.
In part 3, Rebold explores improving the ART formulary protocol through introducing pharmacist-led transition-of-care services.
Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.
A new option for adults who have experienced stroke will now be available to further reduce future risk.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Adds NAION Eye Risk Warning to All GLP-1 Labels
2
The Pharmacy Model Creating New Billing Pathways, Improved Recognition
3
New Report Finds Pharmacies Key in Long-Term GLP-1 Success
4
Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals
5